Nicholas Short, MD

Nicholas Short, MD

The University of Texas MD Anderson Cancer Center

Latest Content

Optic Study Informs Ponatinib Dosing and Treatment Sequencing in CML - Ep. 2 image featuring Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Jane Apperley, Dr. Elias Jabbour, Dr. Nicholas Short, and Dr. Hagop.

CML and Ph+ ALL

11/05/2026

Ep. 2: OPTIC Study Informs Ponatinib Dosing and Treatment Sequencing in CML

OncUpdates Ep. 1 treatment selection and sequencing strategies for chronic-phase CML with expert doctors: Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Jane Apperley, Dr. Elias Jabbour, Dr. Nicholas Short,.

CML and Ph+ ALL

10/29/2026

Ep. 1: Treatment Selection and Sequencing Strategies for Chronic-Phase CML

Panel of five medical experts discussing CML and Ph+ ALL treatment strategies at OncUpdates.

CML and Ph+ ALL

10/22/2026

Experts Discuss Treatment Options for CML and Ph-Positive ALL

OncUpdates episode 4 features experts discussing FLT3-Positive AML targeted therapy from diagnosis through long-term management.

FLT3-Mutated AML

07/28/2026

Ep. 4: FLT3-Mutated AML: Targeted Therapy From Diagnosis Through Long-Term Management

OncUpdates episode 3 featuring experts discussing FLT3-mutated AML, maintenance therapy, triplet regimens, and relapse management.

FLT3-Mutated AML

07/27/2026

Ep. 3: FLT3-Mutated AML: Maintenance Therapy, Triplet Regimens, and Relapse Management

Experts discuss FLT3 inhibitors expanding treatment options in acute myeloid leukemia at OncUpdates.

FLT3-Mutated AML

07/24/2026

Ep. 2: FLT3 Inhibitors Continue to Expand Treatment Opportunities in Acute Myeloid Leukemia

Panel of five medical professionals discussing FLT3-mutated AML treatment strategies in a clinical setting.

FLT3-Mutated AML

07/23/2026

Ep. 1: Optimizing FLT3-Mutated AML Through Precision Testing and Targeted Therapy

Group of five leukemia specialists discussing FLT3 inhibitors in AML treatment, featuring Dr. Nicholas Short, Dr. Uma Borate, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Naval Dayer.

FLT3-Mutated AML

07/13/2026

Leukemia Specialists Review the Role of FLT3 Inhibitors Across AML Treatment Settings